Answers are grounded in this paper and cite their sources.
Case report highlights risks of intravenous flupentixol administration in schizophrenia, suggesting need for proper techniques and monitoring.
Schizophrenia, affecting 1% of the population, often leads to poor outcomes due to medication noncompliance. Long-acting injectable (LAI) antipsychotics like flupentixol help maintain stable drug levels, reducing relapse risks. This case report describes a 26-year-old woman with schizophrenia and erratic medication adherence, resulting in multiple relapses. An inadvertent intravenous injection of flupentixol LAI, instead of the intended intramuscular route, led to her being monitored in the intensive care unit. The patient experienced mild symptoms, including irritability and tachycardia, but stabilized within 24 h with no severe adverse effects. The case illustrates the critical need for correct administration techniques for LAI antipsychotics and immediate intervention in case of errors. The patient’s rapid recovery may be attributed to flupentixol’s pharmacokinetics, including high protein binding and rapid clearance. This report highlights the importance of vigilance and corrective measures to manage and prevent potential complications from improper drug administration.
No takes yet. Share an insight, caveat, or question.
Jilani et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: